Evaluating a Combination of Immune-based Therapies to Achieve a Functional Cure of HIV Infection

Informations projet

HIVACAR

N° de convention de subvention: 731626

DOI

10.3030/731626

Projet clôturé

Date de signature de la CE 12 Decembre 2016

Date de début 1 Janvier 2017

Date de fin 30 Juin 2022

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total

€ 6 822 299,13

Contribution de l’UE

€ 6 685 111,00

Coordonné par

FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Spain

CORDIS fournit des liens vers les livrables publics et les publications des projets HORIZON.

Les liens vers les livrables et les publications des projets du 7e PC, ainsi que les liens vers certains types de résultats spécifiques tels que les jeux de données et les logiciels, sont récupérés dynamiquement sur OpenAIRE .

Livrables

Documents, reports (8)

HIVACAR Phase I/IIa clinical trial protocol

HIVACAR Phase I/IIa clinical trial protocol: A document containing the description of the clinical trial, the research brochure and all other documents requested by the MEC’s for all sites of clinical intervention.

Final report on dissemination activities

Final report on dissemination activities A detailed list of all dissemination activities carried out during the project with assessment of their impact and degree of compliance with the plan

Data Management Plan

The Data Management Plan will be prepared at month 12 and an updated version will be delivered at month 30.

Final Briefing Document sent to EMA to request Scientific Advice containing information on the quality, nonclinical and clinical development program
Final exploitation and sustainability plan

Final exploitation and sustainability plan This report will analyse the exploitation and sustainability models to exploit and promote the use of the HIVACAR results beyond the project life

Intermediate report on dissemination activities

Intermediate report on dissemination activities: A detailed list of dissemination activities carried out halfway through the project, with assessment of their impact, the degree of compliance with the plan, and a description of foreseen dissemination activities until the end of the project.

Targeted communication tools

Targeted communication tools: This deliverable includes tools such as: 1) The review and adaption of the clinical trial synopsis and informative materials to be shared with the participants and the community; 2) Creation of leaflets and other informative materials informing on the project objectives and expected outcomes; 3) The creation of a communication tool (such as an online forum) where the patients enrolled in the clinical trial can raise questions regarding the trial development, share their concerns and expectations regarding their participation. The tool will also allow monitoring and prevent possible dropouts and to manage expectations regarding the outcomes of the project.

Final assessment of the project

Final assessment of the project At the end of the project a final assessment of the degree of fulfilment of the objectives of the project including an assessment of the use cases will be carried out and reported in this deliverable For both D13 and D14 the responsible of performing the assessment of the project will be the project coordinator Dr Felipe Garca with the input and advice from both the Steering Committee and the Scientific Advisory Board

Other (2)

First study subject approvals package

- Final version of study protocol as submitted to regulators / ethics committees- Registration number of clinical study in a WHO- or ICMJE- approved registry - Approvals (ethics committees and national competent authority) required for invitation / enrolment of first subject in at least one clinical centre

Communication plan

Communication plan: This document will describe in detail the project communication strategy in all of its components: objectives, audiences, actions and tools.

Publications

Peer reviewed articles (2)

A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses

Auteurs: Beatriz Perdiguero, Cristina Sánchez-Corzo, Carlos Oscar S. Sorzano, Lidia Saiz, Pilar Mediavilla, Mariano Esteban, Carmen Elena Gómez
Publié dans: Viruses, Numéro 11(2), 2019, Page(s) 160, ISSN 1999-4915
Éditeur: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/v11020160

Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B

Auteurs: Beatriz Perdiguero; Suresh C. Raman; Cristina Sánchez-Corzo; Carlos Oscar S. Sorzano; José Ramón Valverde; Mariano Esteban; Carmen Elena Gómez
Publié dans: Viruses, Numéro 10(8), 2018, Page(s) 424, ISSN 1999-4915
Éditeur: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/v10080424